Related Experiment Video
Updated: Jun 24, 2025
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
A PDE3A-SLFN12 Molecular Glue Exhibits Significant Antitumor Activity in TKI-Resistant Gastrointestinal Stromal
Emiri O Takaki1, Kunihiko Kiyono2, Yutaka Obuchi1
1Department of Medical Innovations, Osaka Research Center for Drug Discovery, Otsuka Pharmaceutical Co., Ltd., Minoh, Japan.
Purpose:
Gastrointestinal stromal tumor (GIST), the most common mesenchymal tumor with KIT or PDGFRA driver mutations, is typically treated with tyrosine kinase inhibitors (TKI). However, resistance to TKIs due to secondary mutations is a common challenge in advanced GISTs. In addition, there are currently no effective therapies for several other molecular subtypes, such as succinate dehydrogenase-deficient GISTs. Therefore, novel therapeutic strategies are needed.
Experimental Design:
To address this need, we tested the efficacy of a novel non-TKI compound, OPB-171775, using patient-derived xenograft models of GISTs. In parallel, we sought to elucidate the mechanism of action of the compound.
Results:
Our study revealed that OPB-171775 exhibited significant efficacy against GISTs regardless of their KIT mutation status by inducing complex formation between phosphodiesterase 3A (PDE3A) and Schlafen family member 12 (SLFN12), which are highly expressed in GISTs, leading to SLFN12 RNase-mediated cell death. Furthermore, we identified the activation of general control non-derepressible 2 and its downstream response as an effector pathway of SLFN12 in mediating anticancer activity and revealed potential pharmacodynamic markers.
Conclusions:
These findings suggest that OPB-171775, with its significant efficacy, could potentially serve as a novel and effective treatment option for advanced GISTs, particularly those resistant to TKIs.
Insights
A new drug, OPB-171775, shows promise for treating gastrointestinal stromal tumors (GISTs). It effectively targets GISTs, including those resistant to current therapies, by inducing cancer cell death.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Gastrointestinal stromal tumors (GISTs) are common mesenchymal tumors driven by KIT or PDGFRA mutations.
- Tyrosine kinase inhibitors (TKIs) are standard GIST treatment but face resistance from secondary mutations.
- Existing therapies are ineffective for some GIST subtypes, like those deficient in succinate dehydrogenase.
Purpose of the Study:
- To evaluate the efficacy of a novel non-TKI compound, OPB-171775, against GISTs.
- To investigate the mechanism of action of OPB-171775.
- To identify potential therapeutic strategies for advanced and TKI-resistant GISTs.
Main Methods:
- Patient-derived xenograft models of GISTs were used to test OPB-171775 efficacy.
- The study elucidated the compound's mechanism of action.
- Potential pharmacodynamic markers were identified.
Main Results:
- OPB-171775 demonstrated significant efficacy across various GISTs, irrespective of KIT mutation status.
- The compound induces cell death by forming a complex between PDE3A and SLFN12, leading to SLFN12 RNase activity.
- The general control non-derepressible 2 pathway was identified as crucial for OPB-171775's anticancer effects.
Conclusions:
- OPB-171775 shows potential as a novel therapeutic for advanced GISTs.
- The compound is effective against TKI-resistant GISTs.
- The PDE3A-SLFN12 interaction and downstream pathways offer new therapeutic targets.
More Related Videos
07:21Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
